논문 상세보기

대한간암학회> 대한간암학회지> 증례 : Intensity Modulated Radiotherapy 및 Cyberknife 치료 증례 ; 동시 항암 화학-방사선 요법 후 근치적 간절제술을 시행한 제4기 간세포암종 1예

KCI등재

증례 : Intensity Modulated Radiotherapy 및 Cyberknife 치료 증례 ; 동시 항암 화학-방사선 요법 후 근치적 간절제술을 시행한 제4기 간세포암종 1예

Curative Resection of Advanced Hepatocellular Carcinoma (TNM stage 4a) after Concurrent Chemo-Radiation Therapy: A Case Report

김도영 ( D. Y. Kim ) , 한광협 ( K. H. Han ) , 성진실 ( J. S. Sung ) , 안상훈 ( S. H. Ahn ) , 김경식 ( K. S. Kim ) , 문창모 ( C. M. Moon ) , 김경규 ( K. K. Kim ) , 박영년 ( Y. N. Park ) , 전재윤 ( C. Y. Chon ) , 문영명 ( Y. M. Moon )
  • : 대한간암학회
  • : 대한간암학회지 5권0호
  • : 연속간행물
  • : 2005년 06월
  • : 22-26(5pages)
대한간암학회지

DOI


목차


					

키워드 보기


초록 보기


UCI(KEPA)

I410-ECN-0102-2009-510-002013840

간행물정보

  • : 의약학분야  > 내과학
  • : KCI등재
  • :
  • : 반년간
  • : 2288-8128
  • : 2283-5001
  • : 학술지
  • : 연속간행물
  • : 2001-2021
  • : 528


저작권 안내

한국학술정보㈜의 모든 학술 자료는 각 학회 및 기관과 저작권 계약을 통해 제공하고 있습니다.

이에 본 자료를 상업적 이용, 무단 배포 등 불법적으로 이용할 시에는 저작권법 및 관계법령에 따른 책임을 질 수 있습니다.

21권2호(2021년 09월) 수록논문
최근 권호 논문
| | | |

KCI등재

1Liver transplantation for hepatocellular carcinoma with portal vein tu-mor thrombosis

저자 : Sang Jin Kim , Jong Man Kim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 21권 2호 발행 연도 : 2021 페이지 : pp. 105-112 (8 pages)

다운로드

(기관인증 필요)

초록보기

Traditionally, liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis is not recommended. However, with recent developments in locoregional therapies for hepatocellular carcinoma, more aggressive treatments have been attempted for advanced hepatocellular carcinoma. Recently, various studies on locoregional therapies for downstaging followed by living donor liver transplantation reported inspiring overall survival and recurrence-free survival of patients. These downstaging procedures included threedimensional conformal radiation therapy, trans-arterial chemoembolization, stereotactic body radiation therapy, trans-arterial radioembolization, hepatic arterial infusion chemotherapy and combinations of these therapies. Selection of the optimal downstaging protocol should depend on tumor location, biology and background liver status. The risk factors affecting outcome include pre-downstaging alpha-fetoprotein values, delta alpha-fetoprotein values, disappearance of portal vein tumor thrombosis on imaging and meeting the Milan criteria or not after downstaging. For hepatocellular carcinoma with portal vein tumor thrombosis, downstaging procedure with liver transplantation in mind would be helpful. If the reaction of the downstaged tumor is good, liver transplantation may be performed. (J Liver Cancer 2021;21:105-112)

KCI등재

2Differences in radiotherapy application according to regional disease characteristics of hepatocellular carcinoma

저자 : Chai Hong Rim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 21권 2호 발행 연도 : 2021 페이지 : pp. 113-123 (11 pages)

다운로드

(기관인증 필요)

초록보기

There are differences in opinion regarding the application of external beam radiotherapy in the treatment of hepatocellular carcinoma. Some major guidelines state that external beam radiotherapy is yet to attain a sufficient level of evidence. However, caution should be exercised when attempting to understand the clinical need for external beam radiotherapy solely based on the level of evidence. Previously, external beam radiotherapy had low applicability in the treatment of hepatocellular carcinoma before computed tomography-based planning was popularized. Modern external beam radiotherapy can selectively target tumor cells while sparing normal liver tissues. Recent technologies such as stereotactic body radiotherapy have enabled more precise treatment. The characteristics of hepatocellular carcinoma differ significantly according to the regional etiology. The main cause of hepatocellular carcinoma is the hepatitis B virus. It is commonly diagnosed as a locally advanced tumor but with relatively preserved hepatic function. The majority of these hepatocellular carcinoma cases are found in the East Asian population. Hepatocellular carcinoma caused by hepatitis C virus or other benign hepatitis tends to be diagnosed as a less locally aggressive tumor but with deteriorated liver function. The western world and Japan tend to have patients with such causes. External beam radiotherapy has been more commonly performed for the former, although the use of external beam radiotherapy in the latter might have more concerns with regard to hepatic toxicity. This review discusses the above subjects along with perspectives regarding external beam radiotherapy in recent guidelines. (J Liver Cancer 2021;21:113-123)

KCI등재

3Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment

저자 : Bo Hyun Kim , Joong-won Park

발행기관 : 대한간암학회 간행물 : 대한간암학회지 21권 2호 발행 연도 : 2021 페이지 : pp. 124-138 (15 pages)

다운로드

(기관인증 필요)

초록보기

Several molecular-targeted agents have been tested as first- or second-line therapies for hepatocellular carcinoma (HCC) but failed to improve clinical outcomes; sorafenib has been the only approved systemic agent for treating HCC for almost 10 years. Regorafenib resulted in a significant improvement in overall survival and thus was approved for HCC patients previously treated with sorafenib. Subsequently, cabozantinib and ramucirumab demonstrated superior overall survival compared with placebos in phase III clinical trials. Immune checkpoint inhibitors such as nivolumab with or without ipilimumab and pembrolizumab are also available in some countries for patients who are unresponsive to sorafenib. Some second-line agents are available for patients who are unresponsive to sorafenib; however, little is known about the considerations for selecting appropriate secondline systemic agents. Hence, this study aimed to review the current and future perspectives of second-line systemic agents. (J Liver Cancer 2021;21:124-138)

KCI등재

4Advances in immune checkpoint inhibitors for hepatocellular carcinoma

저자 : Ji Won Han , Su-hyung Park

발행기관 : 대한간암학회 간행물 : 대한간암학회지 21권 2호 발행 연도 : 2021 페이지 : pp. 139-145 (7 pages)

다운로드

(기관인증 필요)

초록보기

Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading cause of cancer-related death worldwide. Although recent advances in immune checkpoint inhibitor-based immunotherapy have initiated a new era for advanced HCC treatment, the majority of HCC patients receiving immune checkpoint blockades do not derive clinical benefit. Thus, there remains an urgent need for novel immunotherapeutic strategies with improved therapeutic efficacy. Here we review recent studies of immune checkpoint blockade in HCC, providing the necessary basis for the rational design of immunotherapy. (J Liver Cancer 2021;21:139-145)

KCI등재

5Transarterial chemoembolization using drug-eluting bead compared with radiofrequency ablation for treatment of single small hepatocellu-lar carcinoma: a pilot non-randomized trial

저자 : Tae Hoon Kim , Na Hye Kim , Jin Dong Kim , Young Nam Kim , Yu Jin Kim , Eun Jung Kim , Ki Deok Yoo , Choong Heon Ryu , Ha Hun Song , Hyun Kim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 21권 2호 발행 연도 : 2021 페이지 : pp. 146-154 (9 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Surgical resection, transplantation, and radiofrequency ablation (RFA) are generally accepted as amenable treatments for small hepatocellular carcinoma (HCC). Recently drug-eluting beads (DEB) which had several treatment advantages were introduced for transarterial chemoembolization (TACE). The aim of this study was to evaluate feasibility and safety of DEB-TACE compared with RFA for the treatment of single small HCC.
Methods: In this pilot non-randomized trial, we assessed retrospective data of 40 patients who underwent DEB-TACE (n=21) or RFA (n=19) for single small (≤3 centimeter in greatest dimension) HCC. The primary outcomes were tumor response and time to recurrence. The secondary outcome was treatment-related complications.
Results: Complete response rate to DEB-TACE and RFA after first follow-up assessment was 90.5% and 94.7%, respectively (P=1.000). During mean follow-up of 87.6 months (95% confidence interval, 74.4-102), 7 patients experienced local recurrence. The 6- and 12-month cumulative local recurrence rate was 5.0% and 21.8% in DEB-TACE vs. 11.1% and 17.0% in RFA group (P=0.877). A total 14 distant intrahepatic recurrences were developed and 12- and 24-month cumulative distant intrahepatic recurrence rate was 20.6% and 42.7% in DEBTACE vs. 17.2% and 36.3% in RFA group (P=0.844). Two patients experienced gangrenous cholecystitis after DEB-TACE requiring cholecystectomy as treatment-related adverse event.
Conclusions: Tumor response and recurrence rate after single session of DEB-TACE or RFA were similar. DEB-TACE could be applied selectively in patients with a single small HCC if the other therapeutic modality is unfeasible. (J Liver Cancer 2021;21:146-154)

KCI등재

6The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency abla-tion for hepatitis B virus-related hepatocellular carcinoma

저자 : Jae Min Park , Won Hyeok Choe , Jeong Han Kim , So Young Kwon , Byung Chul Yoo

발행기관 : 대한간암학회 간행물 : 대한간암학회지 21권 2호 발행 연도 : 2021 페이지 : pp. 155-162 (8 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Because hepatitis B virus (HBV) replication has been known to play an important role in cancer recurrence after curative treatment of HBV-related hepatocellular carcinoma (HCC), we examined whether treatment based on nucleos(t)ide analogues (NAs) might decrease the recurrence rate and improve patient survival.
Methods: The retrospective cohort study enrolled 73 patients with chronic hepatitis B who were treated with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) with curative intent for HCC. Among those, 30 and 43 patients were treated with tenofovir disoproxil fumarate (TDF) and entecavir (ETV), respectively.
Results: Of the 73 patients, 51 experienced HCC recurrence, and 14 patients were dead during a follow-up of 73±34 months. Multivariate analyses showed that tumor size (hazard ratio [HR], 1.590; 95% confidence-interval [CI], 1.106-2.285; P=0.012) and Child-Pugh class B (vs. class A/non cirrhosis; HR, 5.794; 95% CI, 2.311-14.523; P=0.001) was significantly associated with HCC recurrence, and Child-Pugh class B (HR, 7.357; 95% CI, 2.100-25.777; P=0.002) was an independent unfavorable prognostic factor for survival. During NAs therapy, TDF was superior to ETV for complete viral response at 1 year after the date of combination of TACE and RFA (P=0.016). However, the risks of HCC recurrence and survival were not significantly different between those treated with TDF versus ETV.
Conclusions: TDF was superior to ETV for achieving complete viral response. However, the recurrence and mortality after TACE and RFA for HBV-related HCC were not significantly different between patients treated with TDF versus ETV. (J Liver Cancer 2021;21:155-162)

KCI등재

7Long-term survival after multimodal treatment involving radiotherapy for huge hepatocellular carcinoma with oligometastasis: a case report

저자 : Byung Min Lee , Jinsil Seong

발행기관 : 대한간암학회 간행물 : 대한간암학회지 21권 2호 발행 연도 : 2021 페이지 : pp. 163-168 (6 pages)

다운로드

(기관인증 필요)

초록보기

The clinical efficacy of local ablative treatment for oligometastasis is widely accepted in most cancers. However, due to limited data, this has not been the case for hepatocellular carcinoma (HCC). Here, we report a case of pulmonary oligometastasis of a huge HCC that was treated by multimodality with liver-directed concurrent chemoradiotherapy (CCRT) plus subsequent resection of the primary lesion and local ablative radiotherapy (RT) for subsequent lung oligometastatic lesions. In this patient, liver-directed CCRT induced significant tumor shrinkage with compensatory hypertrophy of the non-tumor liver, followed by curative resection. Surgical resection of the first and second pulmonary metastatic lesions as well as local ablative RT of the third lesion achieved complete tumor regression, which led to long-term survival of 6 years. Therefore, the active use of local ablative RT requires full consideration in cases of oligometastatic HCC. (J Liver Cancer 2021;21:163-168)

KCI등재

8Infiltrative hepatocellular carcinoma with multiple lung metastasis com-pletely cured using nivolumab: a case report

저자 : Ji Eun Han , Hyo Jung Cho , Soon Sun Kim , Jae Youn Cheong

발행기관 : 대한간암학회 간행물 : 대한간암학회지 21권 2호 발행 연도 : 2021 페이지 : pp. 169-176 (8 pages)

다운로드

(기관인증 필요)

초록보기

The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivolumab is used as secondline therapy for advanced HCC after sorafenib failure or patient intolerance. In this case, a patient with infiltrative HCC and portal vein tumor thrombosis was treated with hepatic arterial infusion chemotherapy (HAIC) and radiation therapy. New lung metastasis developed after HAICs; thus, lenvatinib treatment was initiated. However, the disease progressed. Thereafter, sorafenib treatment was initiated but he developed intolerance, with grade 3 sorafenib-related diarrhea. Subsequently, nivolumab was administered as rescue therapy. He demonstrated a partial response to nivolumab after the third treatment and viable HCCs in the lungs and liver completely disappeared after the 24th treatment. These findings suggest that nivolumab could be used as an effective rescue therapy for advanced HCC progression after TKI treatment. (J Liver Cancer 2021;21:169-176)

KCI등재

9Complete response in hepatocellular carcinoma with lymph node metas-tasis by combination therapy of atezolizumab and bevacizumab: a case report

저자 : Sang Youn Hwang , Sun Mi Lee , Jeong Woo Lim , Gi Jung Jeon , Hye Won Lee

발행기관 : 대한간암학회 간행물 : 대한간암학회지 21권 2호 발행 연도 : 2021 페이지 : pp. 177-180 (4 pages)

다운로드

(기관인증 필요)

초록보기

Sorafenib is the oldest first line systemic treatment in patients with advanced hepatocellular carcinoma (HCC) and has been used exclusively for nearly 10 years. The superiority of administering a combination of atezolizumab plus bevacizumab (AteBeva) compared to sorafenib as first line systemic treatment for unresectable HCC was recently proven during the IMbrave150 Phase III randomized trial. While clinicians can expect improved responses and treatment outcomes due to the good results of the IMbrave 150 trial, they must also consider that atezolizumab can cause various immune-related adverse events (IrAEs). Based on the above suggestions, we herein present a case of HCC with lymph node metastasis who achieved complete remission following treatment with AteBeva and developed an IrAE (adrenal insufficiency). Further study of real-life data regarding combination therapy with AteBeva is needed to manage patients with advanced HCC. (J Liver Cancer 2021;21:177-180)

KCI등재

10Curative liver transplantation after lung resection for advanced hepato-cellular carcinoma with lung metastasis and inferior vena cava tumor thrombosis: a case report

저자 : Dong Jin Joo , Do Young Kim , Jinsil Seong , Hyun Jeong Kim , Jae Geun Lee , Dai Hoon Han , Gi Hong Choi , Myoung Soo Kim , Jin Sub Choi , Soon Il Kim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 21권 2호 발행 연도 : 2021 페이지 : pp. 181-186 (6 pages)

다운로드

(기관인증 필요)

초록보기

Hepatocellular carcinoma (HCC) with distant metastasis is an absolute contraindication for liver transplantation (LT). However, it is still unclear whether LT is feasible or acceptable in such patients, albeit after being treated with a multidisciplinary approach and after any metastatic lesion is ruled out. We report one such successful treatment with living donor LT (LDLT) after completely controlling far-advanced HCC with inferior vena cava tumor thrombosis and multiple lung metastases. The patient has been doing well without HCC recurrence for eight years since LDLT. The current patient could be an anecdotal case, but provides a case for expanding LDLT indications in the context of advanced HCC and suchlike. (J Liver Cancer 2021;21:181-186)

12
권호별 보기
같은 권호 다른 논문
| | | | 다운로드

KCI등재

1부록 : 대한간암연구회 회칙

저자 : 학회자료

발행기관 : 대한간암학회 간행물 : 대한간암학회지 5권 0호 발행 연도 : 2005 페이지 : pp. 1-2 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

2종설 : 간세포암종의 정밀 방사선치료

저자 : 성진실 ( Jin Sil Seong )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 5권 0호 발행 연도 : 2005 페이지 : pp. 1-6 (6 pages)

다운로드

(기관인증 필요)

초록보기

KCI등재

3부록 : 증례작성양식(집담회)

저자 : 학회자료

발행기관 : 대한간암학회 간행물 : 대한간암학회지 5권 0호 발행 연도 : 2005 페이지 : pp. 3-6 (4 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

4부록 : 대한간암연구회 투고규정

저자 : 학회자료

발행기관 : 대한간암학회 간행물 : 대한간암학회지 5권 0호 발행 연도 : 2005 페이지 : pp. 7-8 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

5종설 : 간세포암의 고주파 열치료후 합병증

저자 : 임현철 ( Hyun Chul Rhim )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 5권 0호 발행 연도 : 2005 페이지 : pp. 12-17 (6 pages)

다운로드

(기관인증 필요)

초록보기

KCI등재

6종설 : 간세포암종의 화학요법

저자 : 조성원 ( Sung Woo Cho ) , 정재연 ( Jae Youn Cheong )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 5권 0호 발행 연도 : 2005 페이지 : pp. 18-21 (4 pages)

다운로드

(기관인증 필요)

초록보기

KCI등재

7증례 : Intensity Modulated Radiotherapy 및 Cyberknife 치료 증례 ; 동시 항암 화학-방사선 요법 후 근치적 간절제술을 시행한 제4기 간세포암종 1예

저자 : 김도영 ( D. Y. Kim ) , 한광협 ( K. H. Han ) , 성진실 ( J. S. Sung ) , 안상훈 ( S. H. Ahn ) , 김경식 ( K. S. Kim ) , 문창모 ( C. M. Moon ) , 김경규 ( K. K. Kim ) , 박영년 ( Y. N. Park ) , 전재윤 ( C. Y. Chon ) , 문영명 ( Y. M. Moon )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 5권 0호 발행 연도 : 2005 페이지 : pp. 22-26 (5 pages)

다운로드

(기관인증 필요)

초록보기

KCI등재

8증례 : Intensity Modulated Radiotherapy 및 Cyberknife 치료 증례 ; 간세포암종에서 세기 조절 방사선치료를 시행한 1예

저자 : 심수정 ( Su Jung Shim ) , 성진실 ( Jin Sil Seong )

발행기관 : 대한간암학회 간행물 : 대한간암학회지 5권 0호 발행 연도 : 2005 페이지 : pp. 27-29 (3 pages)

다운로드

(기관인증 필요)

초록보기

KCI등재

9증례 : Intensity Modulated Radiotherapy 및 Cyberknife 치료 증례 ; 사이버나이프로 치료한 간세포암종 4예

저자 : 이소연 ( So Yeon Lee ) , 배시현 ( Si Hyun Bae ) , 김민수 ( Min Su Kim ) , 장정원 ( Jeong Won Jang ) , 최종영 ( Jong Young Choi ) , 윤승규 ( Seung Kew Yoon ) , 한준열 ( Joon Yeol Han ) , 정규원 ( Kyu Won Chung ) , 강영남 ( Young Nam Kang ) , 최병옥 ( Byung Ock Choi ) , 최일봉 ( Ihl Bohng

발행기관 : 대한간암학회 간행물 : 대한간암학회지 5권 0호 발행 연도 : 2005 페이지 : pp. 30-36 (7 pages)

다운로드

(기관인증 필요)

초록보기

KCI등재

10증례 : Intensity Modulated Radiotherapy 및 Cyberknife 치료 증례 ; 삼차원 입체조형 방사선치료 후 호전을 보인 간세포암종 2예

저자 : 박경우 ( Kyung Woo Park ) , 박중원 ( Joong Won Park ) , 조상형 ( Sang Hyung Cho ) , 김영일 ( Young Il Kim ) , 김성훈 ( Seong Hoon Kim ) , 박홍석 ( Hong Suk Park ) , 이우진 ( Woo Jin Lee ) , 박상재 ( Sang Jae Park ) , 김대용 ( Dae Young Kim ) , 홍은경 ( Eun Kyoung Hong ) , 김창민 ( Chang

발행기관 : 대한간암학회 간행물 : 대한간암학회지 5권 0호 발행 연도 : 2005 페이지 : pp. 37-41 (5 pages)

다운로드

(기관인증 필요)

초록보기
12
발행기관 최신논문
자료제공: 네이버학술정보
발행기관 최신논문
자료제공: 네이버학술정보

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기